Novo Nordisk’s $4.1B Clayton Facility to Add 1,000 Jobs by Mark Eisenberg 25.06.2024 Novo Nordisk's $4.1B Clayton investment creates 1,000 jobs, boosts local economy, and enhances life science growth in North Carolina.
AbbVie Sets $1.55 Quarterly Dividend, Piper Sandler Ups Target by Mark Eisenberg 22.06.2024 AbbVie sets quarterly dividend at $1.55 per share, showcasing financial health and strategic growth. Recent acquisitions bolster positive outlook.
Fortress Biotech Sees Upgrades Amid Investor Shifts by Lilu Anderson 20.06.2024 "Fortress Biotech (FBIO) upgraded to 'Hold' by StockNews.com amid 5.8% decline; analysts offer mixed ratings as hedge funds increase stakes."
Wake Tech Begins Construction on Advanced Tech Center by Lilu Anderson 19.06.2024 Wake Tech breaks ground on a $60M Advanced Technology Center in Wendell, offering state-of-the-art biopharma and manufacturing training. Opens spring ...
Day One Biopharma Expands to ADCs with $55M Drug Acquisition by Lilu Anderson 19.06.2024 "Day One Biopharmaceuticals enhances pipeline, acquiring global rights to promising PTK7-targeting cancer drug DAY301, begins trial soon."
Avidity Biosciences Director Sells $3.8M in Stock by Mark Eisenberg 15.06.2024 Arthur A. Levin sells 40K Avidity shares; BofA ups target to $45 as FDA advances myotonic dystrophy treatment. AI-assisted article ...
Japer Therapeutics Financial Report: Strong Performance in NASDAQ by Mark Eisenberg 30.03.2024 Explore the intriguing stock volatility of Japer Therapeutics on NASDAQ as it experiences notable fluctuations, urging investors to delve deeper ...
Cabaletta Bio Inc: Financial Report Reveals Market Insights by Mark Eisenberg 30.03.2024 Delve into a comprehensive financial analysis of Cabaletta Bio Inc, a key player in the NASDAQ exchange, with a strong ...
FBIO Stock Soars: Fortress Biotech Beats Q4 Earnings by Mark Eisenberg 29.03.2024 Fortress Biotech's Q3 earnings per share of -53 cents exceeded the analyst estimate of -$1.97 while revenue of $19.95 million ...
Fortress Biotech Q4 Earnings Report: Analysts Predicted Loss by Mark Eisenberg 29.03.2024 Fortress Biotech Inc's shares dropped 27.9% this quarter, exceeding analysts' predicted loss of $1.97 per share.